miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1
Citations Over TimeTop 10% of 2016 papers
Abstract
Drug resistance is one of the leading causes of failed cancer therapy in the treatment of acute myeloid leukemia. Although the mechanisms of resistance are poorly understood, they may be related to the presence of leukemia stem cells (LSCs). Down-regulation of the miR-203 reportedly contributes to oncogenesis and chemo-resistance in multiple cancers. We found that miR-203 expression was down-regulated in CD34 + AML cells as compared with CD34- cells isolated from patients as well as in LSC-enriched (CD34 + CD38-) cell lines KG-1a or MOLM13. Additionally, re-expression of miR-203 led to decreased cell proliferation, self-renewal, and sphere formation in LSCs. Moreover, miR-203 was found to directly target the 3'un-translated regions of survivin and Bmi-1 mRNAs affecting proliferation and self-renewal in LSCs. In this study, we identified a novel miR-203/survivin/Bmi-1 axis involved in the regulation of biological properties of LSCs. This axis may represent a new therapeutic target for acute myeloid leukemia and a potential prognosis/diagnostic marker for LSCs therapy.
Related Papers
- → CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia(2016)42 cited
- → HIV-1 infection depletes human CD34+CD38- hematopoietic progenitor cells via pDC-dependent mechanisms(2017)39 cited
- → CD34+/CD38−acute myelogenous leukemia cells aberrantly express Aurora kinase A(2013)35 cited
- → Phenotypic Characterization of Normal and CML CD34–Positive Cells: Only the Most Primitive CML Progenitors Include Ph-neg Cells(1993)9 cited
- [Expression of beta 2 integrins and L-selectin on CML cells after treatment with IFN-alpha and allo-bone marrow transplantation].(2000)